Spero Therapeutics Files 8-K
Ticker: SPRO · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $25 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
TL;DR
Spero Therapeutics filed an 8-K on 12/19/25, mostly procedural stuff.
AI Summary
On December 19, 2025, Spero Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or transactions detailed in the provided text.
Why It Matters
This 8-K filing indicates Spero Therapeutics is providing updates or submitting required documentation to the SEC, though the specific nature of these events is not detailed in the excerpt.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing any new material information that would immediately impact risk.
Key Numbers
- 001-38266 — Commission File Number (Identifies Spero Therapeutics' SEC filings.)
- 46-4590683 — IRS Employer Identification No. (Tax identification for Spero Therapeutics.)
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- December 19, 2025 (date) — Date of earliest event reported
- 001-38266 (other) — Commission File Number
- 46-4590683 (other) — I.R.S. Employer Identification No.
- 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 (address) — Address of principal executive offices
FAQ
What specific 'Other Events' are being reported by Spero Therapeutics on December 19, 2025?
The provided text does not specify the details of the 'Other Events' reported in the 8-K filing.
What is the purpose of filing 'Financial Statements and Exhibits' in this 8-K?
This filing indicates that Spero Therapeutics is submitting financial statements and exhibits as part of its reporting requirements, but the content of these documents is not detailed in the excerpt.
What is Spero Therapeutics' principal executive office address?
Spero Therapeutics' principal executive office is located at 675 Massachusetts Avenue, 14th Floor, Cambridge, Massachusetts 02139.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on December 19, 2025.
What is Spero Therapeutics' Commission File Number?
Spero Therapeutics' Commission File Number is 001-38266.
Filing Stats: 860 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2025-12-19 08:25:48
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
- $25 million — ephritis. The NDA submission triggers a $25 million milestone payment to the Company under
Filing Documents
- d212013d8k.htm (8-K) — 27KB
- 0001193125-25-325821.txt ( ) — 140KB
- spro-20251219.xsd (EX-101.SCH) — 3KB
- spro-20251219_lab.xml (EX-101.LAB) — 18KB
- spro-20251219_pre.xml (EX-101.PRE) — 11KB
- d212013d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 19, 2025 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Executive Officer, Chief Financial Officer and Chief Business Office